Alcohol Use Disorder and Cannabidiol

Part of paid clinical trials in Aurora, Colorado.

Sponsor
University of Colorado, Denver
Study ID
NCT05613608
Phase
PHASE2/PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
21 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cannabidiol — DRUG
    The current study will directly test the hypothesis that a moderate dose of CBD leads to a reduction in alcohol consumption, alcohol craving, peripheral markers of inflammation, and anxiety.
  • Placebo — DRUG
    Placebo arm.

Study Details

This is a double-blind, placebo-controlled, parallel group study designed to assess the efficacy of full spectrum CBD and broad spectrum CBD, compared to a placebo control (PC), to reduce drinking in participants with alcohol use disorder. If eligible for the study, subjects will be randomized to receive one of the conditions for 12 weeks.

Key Dates

Start date
Apr 30, 2023
Status verified
Sep 2024
Primary completion
Apr 30, 2027
Completion
Apr 30, 2027

Study Design

Enrollment
180 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Full-Spectrum Cannabidiol
    210mg/day of full-spectrum cannabidiol, containing less than 0.3% THC.
  • Active Comparator: Broad-Spectrum Cannabidiol
    210mg/day of full-spectrum cannabidiol, containing 0.0% THC.
  • Placebo Comparator: Placebo
    210mg/day of hemp seed oil with no cannabinoids present.

Primary Outcome Measure

Change in Drinks per Drinking Day [ Time Frame: 0-12 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Colorado AnschutzAuroraColorado80045
Raeghan Mueller, PhD
[email protected]

Find similar trials in Aurora, CO

By condition
Substance use disorder
By specialty
Behavioral healthAddiction medicine
By research site
University of Colorado Anschutz· Aurora, CO

Related Studies